(ORDO NEWS) — Researchers have studied in detail the effectiveness of bacterial therapy – the use of bacterial toxins to kill cancer cells and activate the immune system – for lung cancer.
They also found out which combinations of this method with other types of treatment can be most successful.
The first developments have already passed preclinical trials, and scientists plan to move on to clinical studies.
Lung cancer is one of the most dangerous cancers. Many of the treatments available today have proven ineffective, leaving patients with very few options.
A new and promising strategy is bacterial therapy, which uses bacterial cells to produce toxins that kill cancer cells and attract the attention of the immune system.
Scientists from Columbia University (USA) have developed a preclinical evaluation algorithm to characterize different types of bacterial therapy in models of lung cancer.
In a study they also compared combinations of these therapies with other more popular cancer treatments to improve their effectiveness and mitigate side effects.
The new approach allowed for the rapid characterization of bacterial therapies and their successful integration with widely used lung cancer therapies.
The authors found out how cancer cells react to bacteria at the cellular and molecular levels.
According to their hypothesis, the molecular characteristics of cancer cells make them resistant to bacterial therapy.
To test their hypothesis, the researchers blocked some of their signaling pathways with modern anti-cancer drugs and showed that in this situation, bacterial toxins are more effective at destroying tumor cells.
So, on the example of laboratory mice with lung cancer, scientists confirmed the effectiveness of a combination of bacterial therapy with the introduction of protein kinase inhibitors, which suppress the growth of cancer cells.
According to the authors, their work provides a compelling rationale for continuing research in this area.
Now they plan to expand their strategy to include larger preclinical studies of intractable lung cancer models, as well as partnering with physicians to advance clinical trials of new methods.
Contact us: [email protected]